Natalizumab effectively prevents disease activity in relapsing-remitting multiple sclerosis by binding α4 integrin and inhibiting leukocyte migration to the central nervous system. We recently reported an association between low natalizumab receptor occupancy and subjective wearing-off symptoms at the end of the 4-week dosing interval. Here, we aimed to evaluate the short-term risk of disease activity in a 1-year prospective follow-up of the same patient cohort (n = 40). We found that all patients available for follow-up after one year (n = 35) fulfilled the criteria for no evidence of disease activity (NEDA). Thus, wearing-off symptoms were not associated with increased short-term risk of disease activity. Longer follow-up in a larger patient cohort is required to establish whether therapeutic efficacy is maintained in patients with wearing-off symptoms.

中文翻译：

---

那他珠单抗给药间隔结束时的磨损和 MS 疾病活动的风险：一项前瞻性 1 年随访研究

那他珠单抗通过结合 α4 整合素并抑制白细胞迁移至中枢神经系统，有效预防复发缓解型多发性硬化症的疾病活动。我们最近报告了在 4 周给药间隔结束时低那他珠单抗受体占有率与主观消退症状之间的关联。在这里，我们旨在评估同一患者队列（n = 40）的 1 年前瞻性随访中疾病活动的短期风险。我们发现一年后可进行随访的所有患者 (n = 35) 均符合无疾病活动证据 (NEDA) 的标准。因此，消退症状与疾病活动的短期风险增加无关。